Posted inCardiology Diabetes & Endocrinology news
Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial
A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differences in baseline clinical profiles.